Substance use disorders in refugee and migrant groups in Sweden: A nationwide cohort study of 1.2 million people.


Journal

PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360

Informations de publication

Date de publication:
11 2019
Historique:
received: 10 06 2019
accepted: 27 09 2019
entrez: 6 11 2019
pubmed: 7 11 2019
medline: 8 2 2020
Statut: epublish

Résumé

Refugees are at higher risk of some psychiatric disorders, including post-traumatic stress disorder (PTSD) and psychosis, compared with other non-refugee migrants and the majority population. However, it is unclear whether this also applies to substance use disorders, which we investigated in a national register cohort study in Sweden. We also investigated whether risk varied by region of origin, age at migration, time in Sweden, and diagnosis of PTSD. Using linked Swedish register data, we followed a cohort born between 1984 and 1997 from their 14th birthday or arrival in Sweden, if later, until an International Classification of Diseases, 10th revision (ICD-10), diagnosis of substance use disorder (codes F10.X-19.X), emigration, death, or end of follow-up (31 December 2016). Refugee and non-refugee migrants were restricted to those from regions with at least 1,000 refugees in the Swedish registers. We used Cox proportional hazards regression to estimate unadjusted and adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) in refugee and non-refugee migrants, compared with Swedish-born individuals, for all substance use disorders (F10.X-19.X), alcohol use disorders (F10.X), cannabis use disorders (F12.X), and polydrug use disorders (F19.X). In adjusted analyses, we controlled for age, sex, birth year, family income, family employment status, population density, and PTSD diagnosis. Our sample of 1,241,901 participants included 17,783 (1.4%) refugee and 104,250 (8.4%) non-refugee migrants. Refugees' regions of origin were represented in proportions ranging from 6.0% (Eastern Europe and Russia) to 41.4% (Middle East and North Africa); proportions of non-refugee migrants' regions of origin ranged from 11.8% (sub-Saharan Africa) to 33.7% (Middle East and North Africa). These groups were more economically disadvantaged at cohort entry (p < 0.001) than the Swedish-born population. Refugee (aHR: 0.52; 95% CI 0.46-0.60) and non-refugee (aHR: 0.46; 95% CI 0.43-0.49) migrants had similarly lower rates of all substance use disorders compared with Swedish-born individuals (crude incidence: 290.2 cases per 100,000 person-years; 95% CI 287.3-293.1). Rates of substance use disorders in migrants converged to the Swedish-born rate over time, indicated by both earlier age at migration and longer time in Sweden. We observed similar patterns for alcohol and polydrug use disorders, separately, although differences in cannabis use were less marked; findings did not differ substantially by migrants' region of origin. Finally, while a PTSD diagnosis was over 5 times more common in refugees than the Swedish-born population, it was more strongly associated with increased rates of substance use disorders in the Swedish-born population (aHR: 7.36; 95% CI 6.79-7.96) than non-refugee migrants (HR: 4.88; 95% CI 3.71-6.41; likelihood ratio test [LRT]: p = 0.01). The main limitations of our study were possible non-differential or differential under-ascertainment (by migrant status) of those only seen via primary care and that our findings may not generalize to undocumented migrants, who were not part of this study. Our findings suggest that lower rates of substance use disorders in migrants and refugees may reflect prevalent behaviors with respect to substance use in migrants' countries of origin, although this effect appeared to diminish over time in Sweden, with rates converging towards the substantial burden of substance use morbidity we observed in the Swedish-born population.

Sections du résumé

BACKGROUND
Refugees are at higher risk of some psychiatric disorders, including post-traumatic stress disorder (PTSD) and psychosis, compared with other non-refugee migrants and the majority population. However, it is unclear whether this also applies to substance use disorders, which we investigated in a national register cohort study in Sweden. We also investigated whether risk varied by region of origin, age at migration, time in Sweden, and diagnosis of PTSD.
METHODS AND FINDINGS
Using linked Swedish register data, we followed a cohort born between 1984 and 1997 from their 14th birthday or arrival in Sweden, if later, until an International Classification of Diseases, 10th revision (ICD-10), diagnosis of substance use disorder (codes F10.X-19.X), emigration, death, or end of follow-up (31 December 2016). Refugee and non-refugee migrants were restricted to those from regions with at least 1,000 refugees in the Swedish registers. We used Cox proportional hazards regression to estimate unadjusted and adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) in refugee and non-refugee migrants, compared with Swedish-born individuals, for all substance use disorders (F10.X-19.X), alcohol use disorders (F10.X), cannabis use disorders (F12.X), and polydrug use disorders (F19.X). In adjusted analyses, we controlled for age, sex, birth year, family income, family employment status, population density, and PTSD diagnosis. Our sample of 1,241,901 participants included 17,783 (1.4%) refugee and 104,250 (8.4%) non-refugee migrants. Refugees' regions of origin were represented in proportions ranging from 6.0% (Eastern Europe and Russia) to 41.4% (Middle East and North Africa); proportions of non-refugee migrants' regions of origin ranged from 11.8% (sub-Saharan Africa) to 33.7% (Middle East and North Africa). These groups were more economically disadvantaged at cohort entry (p < 0.001) than the Swedish-born population. Refugee (aHR: 0.52; 95% CI 0.46-0.60) and non-refugee (aHR: 0.46; 95% CI 0.43-0.49) migrants had similarly lower rates of all substance use disorders compared with Swedish-born individuals (crude incidence: 290.2 cases per 100,000 person-years; 95% CI 287.3-293.1). Rates of substance use disorders in migrants converged to the Swedish-born rate over time, indicated by both earlier age at migration and longer time in Sweden. We observed similar patterns for alcohol and polydrug use disorders, separately, although differences in cannabis use were less marked; findings did not differ substantially by migrants' region of origin. Finally, while a PTSD diagnosis was over 5 times more common in refugees than the Swedish-born population, it was more strongly associated with increased rates of substance use disorders in the Swedish-born population (aHR: 7.36; 95% CI 6.79-7.96) than non-refugee migrants (HR: 4.88; 95% CI 3.71-6.41; likelihood ratio test [LRT]: p = 0.01). The main limitations of our study were possible non-differential or differential under-ascertainment (by migrant status) of those only seen via primary care and that our findings may not generalize to undocumented migrants, who were not part of this study.
CONCLUSIONS
Our findings suggest that lower rates of substance use disorders in migrants and refugees may reflect prevalent behaviors with respect to substance use in migrants' countries of origin, although this effect appeared to diminish over time in Sweden, with rates converging towards the substantial burden of substance use morbidity we observed in the Swedish-born population.

Identifiants

pubmed: 31689291
doi: 10.1371/journal.pmed.1002944
pii: PMEDICINE-D-19-02064
pmc: PMC6830745
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1002944

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 101272/Z/13/Z
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Int J Ment Health Syst. 2015 Jan 20;9:5
pubmed: 25972917
BMJ. 2016 Mar 15;352:i1030
pubmed: 26979256
Br J Psychiatry. 2019 Oct 14;:1-7
pubmed: 31608849
Psychol Med. 2019 Oct;49(14):2354-2363
pubmed: 30514409
BMC Public Health. 2018 May 22;18(1):651
pubmed: 29788931
Arch Gen Psychiatry. 1995 Dec;52(12):1048-60
pubmed: 7492257
PLoS One. 2016 Nov 30;11(11):e0166066
pubmed: 27902694
Am J Addict. 2014 Jul-Aug;23(4):337-42
pubmed: 24961361
Soc Psychiatry Psychiatr Epidemiol. 2002 Aug;37(8):372-9
pubmed: 12195544
Drug Alcohol Depend. 2014 Sep 1;142:345-9
pubmed: 24999058
Int J Drug Policy. 2016 Nov;37:52-59
pubmed: 27588569
Addiction. 2004 Feb;99(2):229-36
pubmed: 14756715
Eur J Public Health. 2007 Oct;17(5):503-7
pubmed: 17251304
J Immigr Minor Health. 2013 Oct;15(5):851-7
pubmed: 22797950
Int J Environ Res Public Health. 2017 Jun 07;14(6):
pubmed: 28590438
Addiction. 2004 Oct;99(10):1298-305
pubmed: 15369568
J Immigr Minor Health. 2015 Aug;17(4):992-1001
pubmed: 25037580
Soc Psychiatry Psychiatr Epidemiol. 2017 Dec;52(12):1523-1540
pubmed: 28856385
Alcohol Clin Exp Res. 2017 Jun;41(6):1137-1143
pubmed: 28470666
Mol Psychiatry. 2009 Nov;14(11):1051-66
pubmed: 18427559
Psychiatry Res. 2014 Dec 30;220(3):1028-36
pubmed: 25223256
Aust N Z J Public Health. 2001 Oct;25(5):464-9
pubmed: 11688629
PLoS One. 2016 Jul 13;11(7):e0159134
pubmed: 27411086
CMAJ. 2011 Sep 6;183(12):E959-67
pubmed: 20603342
CMAJ. 2015 Jun 16;187(9):E279-E286
pubmed: 25964387
Scand J Public Health. 2004;32(1):40-6
pubmed: 14757547
BMJ Open. 2017 Dec 29;7(12):e018899
pubmed: 29289940
Alcohol Alcohol. 2013 May-Jun;48(3):349-55
pubmed: 23443987
Springerplus. 2013 May 14;2(1):222
pubmed: 23853744
Am J Psychiatry. 2011 Dec;168(12):1278-85
pubmed: 22193672
BMC Psychiatry. 2018 Jun 20;18(1):206
pubmed: 29925338
Br J Psychiatry. 2012 Mar;200(3):216-23
pubmed: 22282430
Lancet. 2005 Apr 9-15;365(9467):1309-14
pubmed: 15823380
Stat Methods Med Res. 1999 Mar;8(1):3-15
pubmed: 10347857
JAMA Psychiatry. 2013 Apr;70(4):427-35
pubmed: 23446644
Front Psychiatry. 2018 Aug 28;9:393
pubmed: 30210373
BMC Public Health. 2011 Jun 09;11:450
pubmed: 21658213
JAMA. 2005 Aug 3;294(5):571-9
pubmed: 16077051
BJPsych Open. 2016 Jan 13;2(1):6-9
pubmed: 27703747
J Stud Alcohol Drugs. 2014 Nov;75(6):958-67
pubmed: 25343653
Am J Psychiatry. 2001 Aug;158(8):1184-90
pubmed: 11481147
Int J Environ Res Public Health. 2018 Sep 12;15(9):
pubmed: 30213071
Schizophr Bull. 2017 Oct 21;43(6):1251-1261
pubmed: 28521056

Auteurs

Samantha Harris (S)

Psylife Group, Division of Psychiatry, University College London, London, United Kingdom.
Department of Psychosocial Science, University of Bergen, Bergen, Norway.

Jennifer Dykxhoorn (J)

Psylife Group, Division of Psychiatry, University College London, London, United Kingdom.

Anna-Clara Hollander (AC)

Department of Public Health Sciences, Karolinska Institute, Stockholm, Sweden.

Christina Dalman (C)

Department of Public Health Sciences, Karolinska Institute, Stockholm, Sweden.

James B Kirkbride (JB)

Psylife Group, Division of Psychiatry, University College London, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH